AbCellera Biologics (ABCL) vs Dianthus Therapeutics (DNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed AbCellera Biologics (ABCL) over the past year, gaining 144.6% versus a gain of 122.4%. Over five years, ABCL leads with a -17.4% price change compared with -21.2% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.61 billion vs $3.90 billion), about 1.2 times the size, while AbCellera Biologics is growing revenue faster (+160.6% vs -67.3%).
AbCellera Biologics converts more of its revenue into profit, with a net margin of -194.9% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | DNTH |
|---|---|---|
| Share price | $12.02 | $82.43 |
| Market cap | $3.90B | $4.61B |
| 1-day change | -6.31% | -2.89% |
| YTD return | +275.15% | +105.97% |
| 1-year return | +122.36% | +144.61% |
| 5-year return | -17.39% | -21.17% |
| EPS (TTM) | $-0.54 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $2.04M |
| Revenue growth (YoY) | +160.56% | -67.35% |
| Net income (latest FY) | $-146.41M | $-162.34M |
| Operating margin | -288.98% | -8739.34% |
| Net margin | -194.88% | -7973.33% |
| 52-week high | $15.02 | $117.88 |
| 52-week low | $2.75 | $32.22 |
| Distance from 52-week high | -19.95% | -30.07% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +38.94% | +70.81% |
| Average volume | 6.67M | 821.22K |
| Shares outstanding | 324.05M | 55.93M |
| Employees | 562 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed ABCL by 22.3 percentage points over the past year.
- AbCellera Biologics is more profitable, keeping -194.9 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs -67.35%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
ABCL vs DNTH FAQ
Which is bigger, AbCellera Biologics or Dianthus Therapeutics?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.61B compared with $3.90B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or DNTH?
DNTH returned +144.61% over the past 12 months, compared with +122.36% for ABCL (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Dianthus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.